

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1468R1D1	Serial No. 828739 not yet assigned
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Ashkenazi et al.	
				Filing Date 09 Apr 2001	Group 1644 not yet assigned

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
ad	* 1	4,816,567	28.03.89	Cabilly et al.	530	387,3	
ad	* 2	4,855,235	08.08.89	Takahashi et al.	435	240,27	
ad	* 3	5,071,759	10.12.91	Rothman et al.	435	240,27	
ad	* 4	5,153,118	06.10.92	Wright, Jr. et al.	435	7,23	
ad	* 5	5,158,885	27.10.92	Bradstock et al.	435	240,27	
ad	* 6	5,622,701	22.04.97	Berg, E.	424	153,1	
ad	* 7	6,030,945	29.02.00	Ashkenazi, A.	514	12	
ad	* 8	6,072,047	06.06.00	Rauch et al.	536	23,53	

JC979 U.S. PRO
09/09/01
04/09/01
Barcode

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
ad	* 9	WO 91/02805	07.03.91	PCT	—	—		
ad	* 10	WO 93/22343	11.11.93	PCT	—	—		
ad	* 11	WO 97/05170	13.02.97	PCT	—	—		
ad	* 12	WO 97/25428	17.07.97	PCT	—	—		
ad	* 13	WO 99/03992	28.01.99	PCT	—	—		
ad	* 14	WO 99/09165	25.02.99	PCT	—	—		
ad	* 15	WO 99/64461	16.12.99	PCT	—	—		

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

ad	* 16	Ashkenazi et al., "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin" <u>Proc. Natl. Acad. Sci.</u> 88:10535-10539 (1991)
	* 17	Chuntharapai and Kim, "Generation of Monoclonal Antibodies to Chemokine Receptors" <u>Methods in Enzymology</u> 288:15-27 (1997)
	* 18	Ellis, S., "Recognition of HLA-B27 and Related Antigen by a Monoclonal Antibody" <u>Human Immunology</u> 5:49-59 (1982)
	* 19	Emery et al., "Osteoprotegerin Is a Receptor for the Cytotoxic Ligand Trail" <u>Journal of Interferon and Cytokine Research</u> (Abstract No. 2.17 from the 7th Intl. Tumor Necrosis Factor Congress May 17-21) 18(5):A-47 (May 1998)
	* 20	Fishwild et al., "High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice" <u>Nature Biotechnology</u> 14(7):845-851 (Jul 1996)
	* 21	Glassy, M., "Production methods for generating human monoclonal antibodies" <u>Human Antibodies & Hybridomas</u> 4(4):154-165 (Oct 1993)
	* 22	Hoogenboom and Winter, "By-passing immunisation: human antibodies from synthetic repertoires of germline V _H gene segments rearranged in vitro" <u>J. Mol. Biol.</u> 227:381-388 (1992)
	* 23	Jolliffe, L., "Humanized antibodies: enhancing therapeutic utility through antibody engineering" <u>International Reviews of Immunology</u> 10(2-3):241-250 (1993)
ad	* 24	Jones et al., "Replacing the Complementarity-determining Regions in a Human Antibody with Those From a Mouse" <u>Nature</u> 321:522-525 (May 29, 1986)

Examiner

David A Saunders

Date Considered

9/28/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

• FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P1468R1D1Serial No.
not yet assignedApplicant
Ashkenazi et al.Filing Date
09 Apr 2001Group
not yet assigned

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

<i>Dan</i>	*25	Kohler and Milstein, "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity" <u>Nature</u> 256:495-497 (August 7, 1975)
	*26	Marks et al., "By-passing immunization: human antibodies from V-gene libraries displayed on phage" <u>J. Mol. Biol.</u> 222:581-597 (1991)
	*27	Marsters et al., "A Novel Receptor for Apo2L/TRAIL Contains a Truncated Death Domain" <u>Current Biology</u> 7:1003-1006 (1997)
	*28	Mehta et al., "Simultaneous production of antibodies against T ₃ and T ₄ in a single animal; their characteristics and usefulness in radioimmunoassay" <u>International Journal of Radiation Applications & Instrumentation - Part B, Nuclear Medicine & Biology</u> 16(6):599-601 (1989)
	*29	Mendez et al., "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice" <u>Nature Genetics</u> 15:146-156 (Feb 1997)
	*30	Milstein, C., "The Wellcome Foundation Lecture, 1980: monoclonal antibodies from hybrid myelomas" <u>Proceedings of the Royal Society of London - Series B: Biological Sciences</u> 211(1185):393-412 (Mar 27, 1981)
	*31	Olsson and Kaplan, "Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity" <u>Proc. Natl. Acad. Sci. USA</u> 77(9):5429-5431 (1980)
	*32	Pan et al., "The Receptor for the Cytotoxic Ligand TRAIL" <u>Science</u> 276:111-113 (1997)
	*33	Peterson, N., "Recombinant antibodies: alternative strategies for developing and manipulating murine-derived monoclonal antibodies" <u>Laboratory Animal Science</u> 46(1):8-14 (Feb. 1996)
	*34	Pitti et al., "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family" <u>Journal of Biological Chemistry</u> 271:12687-12690 (1996)
	*35	Riechmann et al., "Reshaping Human Antibodies for Therapy" <u>Nature</u> 332:323-327 (Mar 24, 1988)
	*36	Sheridan et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors" <u>Science</u> 277:818-821 (1997)
	*37	Simonet et al., "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density" <u>Cell</u> 89:309-319 (1997)
	*38	Steinritz et al., "EB virus-induced B lymphocyte cell lines producing specific antibody" <u>Nature</u> 269(5627):420-422 (Sep 29, 1977)
	*39	Vaughan et al., "Human Antibodies With Sub-nanomolar Affinities Isolated From a Large Non-immunized Phage Display Library" <u>Nature Biotechnology</u> 14:309-314 (1996)
	*40	Verhoeven et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" <u>Science</u> 239:1534-1536 (Mar 25, 1988)

Examiner

David A. Saunders

Date Considered

9/28/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.